


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number		10/766,749	
		Filing Date		January 28, 2004	
		First Named Inventor		Joyce C. Knutson	
		Group Art Unit		1614	
		Examiner Name		Not Known	
Sheet	1	of	1	Attorney Docket Number	
				017620/9381	

## U.S. PATENT DOCUMENTS

Examiner Initials	U.S. Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document
<i>SAG</i>	07/227,371	Bone Care International	8/02/1988
	08/275,641	Bone Care International	7/14/1994
	3,907,843	DeLuca et al	9/23/1975
	4,195,027	DeLuca et al	3/25/1980
	4,202,829	DeLuca et al	5/13/1980
	4,225,596	DeLuca	9/30/1980
	4,234,495	DeLuca et al	11/18/1980
	4,260,549	DeLuca et al	4/7/1981
	4,554,106	DeLuca et al	11/19/1995
	4,555,364	DeLuca et al	11/26/1985
	5,063,221	Nishii et al	11/5/1991
<i>SAG</i>	5,707,980	Knutson et al	1/13/1998

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Country Code	Foreign Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Translation	English Abstract

Q:\client\017620\9381\B0375374.1


Examiner Signature	<i>SAG</i>	Date Considered	3/2/05
--------------------	------------	-----------------	--------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden-Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 0231.


DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number		10/766,749	
		Filing Date		January 28, 2004	
		First Named Inventor		Joyce C. Knutson	
		Group Art Unit		1614	
		Examiner Name		Not Known	
Sheet	1	of	2	Attorney Docket Number	
				017620/9381	

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc. ), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
SAD		ALOIA, J. <i>et al.</i> , <i>Amer. J. Med.</i> 84, 401-408 (1988)
		CHRISTIANSEN, C. <i>et al.</i> , <i>Eur. J. Clin. Invest.</i> 11, 305-309 (1981)
		GALLAGHER, J.C., <i>et al.</i> , <i>Annals of Int. Med.</i> 113, 649-655 (1990)
		GALLAGHER, J.C., <i>J. Bone Min. Res.</i> 9, 607-614 (1994)
		HOLICK, M.F., <i>et al.</i> , <i>Proc. Natl. Acad. Sci. USA</i> 68, 803-804 (1971)
		HOLICK, M.F., <i>Science</i> 180, 190-191 (1973)
		JENSEN, G.F., <i>et al.</i> , <i>Clin. Endocrinol.</i> 16, 515-524 (1982)
		JONES, G., <i>et al.</i> , <i>Biochemistry</i> , 14, 1250-1256 (1975)
		KNUTSON, J.C., <i>et al.</i> , <i>Endocrinology</i> 136(11):4749-4753 (November 1995)
SAD		LAM, H.Y., <i>et al.</i> , <i>Science</i> 486, 1038-1040 (1974)

Examiner Signature		Date Considered	3/2/05
--------------------	---	-----------------	--------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO			<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)			Application Number	10/766,749
			Filing Date	January 28, 2004
			First Named Inventor	Joyce C. Knutson
			Group Art Unit	1614
			Examiner Name	Not Known
			Attorney Docket Number	017620/9381
Sheet	2	of	2	

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
SAD	ORIMO, H., et al., <i>Bone and Mineral</i> 3, 47-51 (1987)
	OTT, S.M., C.H. CHESTNUT, <i>Annals of Int. Med.</i> 110, 267-274 (1989)
	SHIRAKI, M., et al., <i>Endocrinol. Japan</i> 32, 305-315 (1985)
	SJODEN, G., et al., <i>J. Nutr.</i> 114, 2043-2046 (1984)
	SJODEN, G., et al., <i>Proc. Soc. Exp. Biol. Med.</i> 178, 432-436 (1985)
	SORENSEN, O.H., et al., <i>Clin Endocrinol</i> 7, 169S-175S (1977)
	STRUGNELL, et al, <i>Biochem. J.</i> 310(1):233-241 (August 15, 1995)
SAD	THE MERCK INDEX, 11th ed. 9932 (1989)

Examiner Signature		Date Considered	3/2/05
-----------------------	---	--------------------	--------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.: 017620-9381

SERIAL NO.: 10/766,749

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT:

APPLICANT: Joyce C. Knutson

(Use several sheets if necessary)

FILING DATE: January 28, 2004

GROUP: 1614



EXAMINER INITIAL	DOCUMENT NUMBER	DATE	APPLICANT	CLASSIFICATION
SAG	2,383,446	6/1941	Calcott <i>et al.</i>	
	3,697,559	10/1972	DeLuca <i>et al.</i>	
	3,741,996	6/1973	DeLuca <i>et al.</i>	
	4,160,803	7/1979	Potts	
	4,341,774	7/1982	Aoki <i>et al.</i>	
	4,362,710	12/1982	Watanabe	
	4,388,243	6/1983	Nishikawa <i>et al.</i>	
	4,391,802	7/1983	Suda <i>et al.</i>	
	4,508,651	4/1985	Baggiolini <i>et al.</i>	
	4,588,716	5/1986	DeLuca <i>et al.</i>	
	4,652,405	3/1987	Partridge <i>et al.</i>	
	4,661,294	4/1987	Holick <i>et al.</i>	
	4,670,190	6/1987	Hesse <i>et al.</i>	
	4,689,180	8/1987	DeLuca <i>et al.</i>	
	4,698,328	10/1987	Neer <i>et al.</i>	
	4,717,721	1/1988	DeLuca <i>et al.</i>	
	4,749,710	6/1988	Truitt <i>et al.</i>	
	4,833,125	5/1989	Neer <i>et al.</i>	
	4,866,048	9/1989	Calverley <i>et al.</i>	
	4,891,364	1/1990	Kubodera <i>et al.</i>	
	4,897,388	1/1990	Malluche	
	4,902,481	2/1990	Clark <i>et al.</i>	
	4,929,610	5/1990	Meier, <i>et al.</i>	
	4,948,789	8/1990	Slatopolsky	
	5,035,783	7/1991	Goethals <i>et al.</i>	
	5,098,899	3/1992	Gilbert <i>et al.</i>	
	5,104,864	4/1992	DeLuca <i>et al.</i>	
	5,141,719	8/1992	Fernwood <i>et al.</i>	
	5,157,135	10/1992	Tsuji <i>et al.</i>	
	5,190,935	3/1993	Binderup <i>et al.</i>	
	5,205,989	4/1993	Aysta	
	5,206,229	4/1993	Calverley <i>et al.</i>	
	5,219,528	6/1993	Clark	
	5,232,836	8/1993	Bouillon <i>et al.</i>	
	5,250,523	10/1993	DeLuca <i>et al.</i>	
	5,252,191	10/1993	Pauli <i>et al.</i>	
	5,260,290	11/1993	DeLuca <i>et al.</i>	
	5,264,184	11/1993	Aysta <i>et al.</i>	

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE  
(Rev. 2-92) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.: 017620-9381

SERIAL NO.: 10/766,749

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT:

APPLICANT: Joyce C. Knutson.

(Use several sheets if necessary)

FILING DATE: January 28, 2004

GROUP: 1614

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	APPLICANT	CLASSIFICATION
<i>SAC</i>	5,264,618	11/1993	Felgner <i>et al.</i>	
	5,304,291	4/1994	Bout <i>et al.</i>	
	5,334,740	8/1994	Takahashi <i>et al.</i>	
	5,338,532	8/1994	Tomalia <i>et al.</i>	
	5,350,745	9/1994	Gulbrandsen <i>et al.</i>	
	5,366,965	11/1994	Strein, Klaus	
	5,372,996	12/1994	Labrie	
	5,374,629	12/1994	Calverley <i>et al.</i>	
	5,403,831	4/1995	DeLuca <i>et al.</i>	
	5,414,098	5/1995	DeLuca <i>et al.</i>	
	5,417,923	5/1995	Bojanic <i>et al.</i>	
	5,449,668	9/1995	Sestelo <i>et al.</i>	
	5,488,120	1/1996	Knutson <i>et al.</i>	
	5,518,725	5/1996	Daynes <i>et al.</i>	
	5,527,524	6/1996	Tomalia	
	5,540,919	7/1996	Daynes <i>et al.</i>	
	5,554,386	9/1996	Groman <i>et al.</i>	
	5,559,107	9/1996	Gates <i>et al.</i>	
	5,561,123	10/1996	DeLuca <i>et al.</i>	
	5,562,910	10/1996	Daynes <i>et al.</i>	
	5,585,368	12/1996	Steinmeyer <i>et al.</i>	
	5,589,471	12/1996	Hansen <i>et al.</i>	
	5,597,575	1/1997	Breitbarth	
	5,602,116	2/1997	Knutson <i>et al.</i>	
	5,614,513	3/1997	Knutson <i>et al.</i>	
	5,637,742	6/1997	Valles <i>et al.</i>	
	5,661,025	8/1997	Szoka Jr. <i>et al.</i>	
	5,665,387	9/1997	Mathieu <i>et al.</i>	
	5,691,328	11/1997	Peterson <i>et al.</i>	
	5,700,791	12/1997	Steinmeyer <i>et al.</i>	
	5,707,980	1/1998	Knutson <i>et al.</i>	
	5,710,142	1/1998	Calverley <i>et al.</i>	
	5,710,294	1/1998	DeLuca <i>et al.</i>	
	5,716,946	2/1998	DeLuca <i>et al.</i>	
	5,739,271	4/1998	Sridhar <i>et al.</i>	
	5,750,517	5/1998	Baggiolini <i>et al.</i>	
<i>SAC</i>	5,750,746	5/1998	DeLuca <i>et al.</i>	
	5,756,783	5/1998	Knutson <i>et al.</i>	

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE  
(Rev. 2-92) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.: 017620-9381

SERIAL NO.: 10/766,749

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT:

APPLICANT: Joyce C. Knutson.

(Use several sheets if necessary)

FILING DATE: January 28, 2004

GROUP: 1614

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	APPLICANT	CLASSIFICATION
<i>SAJ</i>	5,795,882	8/1998	Bishop <i>et al.</i>	
	5,869,473	2/1999	Knutson <i>et al.</i>	
	5,972,917	10/1999	Bishop <i>et al.</i>	
	6,242,434	6/2001	Bishop <i>et al.</i>	
	6,376,479	4/2002	Knutson <i>et al.</i>	
	6,521,608	2/2003	Henner <i>et al.</i>	
	6,537,982	3/2003	Bishop <i>et al.</i>	
	6,572,603	6/2003	Tani <i>et al.</i>	
<i>SAJ</i>	6,579,861	6/2003	DeLuca <i>et al.</i>	

#### FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO
<i>SAJ</i>	EP 0 503 630 A1	9/1992	Europe	
	EP 0 562 497 A1	9/1993	Europe	
	EP 0 664 287 B1	7/1995	Europe	
	EP 0 197 514 A1	10/1986	Europe	
	EP 0 197 514 B1	10/1986	Europe	
	EP 0 381 750 B1	8/1990	Europe	
	AU 719773	8/2000	Australia	
	CA 2,217,260	8/2000	Canada	
	NZ 316662	3/2001	New Zealand	
	WO 84/04527	11/1984	PCT	
	WO 90/01321	2/1990	PCT	
	WO 92/05130	4/1992	PCT	
	WO 92/12165	7/1992	PCT	
	WO 93/14763	8/1993	PCT	
	WO 94/00128	1/1994	PCT	
	WO 94/05630	3/1994	PCT	
	WO 94/16711	8/1994	PCT	
	WO 96/31215	10/1996	PCT	
	WO 96/40154	12/1996	PCT	
	AU 634490	6/1993	Australia	
	JP 6025039	2/1994	Japan	English Abstract X
<i>SAJ</i>	JP 62000033	1/1987	Japan	English Abstract X
	JP 5320127	12/1993	Japan	English Abstract X

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered; whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE  
(Rev. 2-92) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.: 017620-9381

SERIAL NO.: 10/766,749

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT:

APPLICANT: Joyce C. Knutson.

(Use several sheets if necessary)

FILING DATE: January 28, 2004

GROUP: 1614

### FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
SAC	HU 207040 B	3/1993	Hungary	English Abstract of EP equivalent	X
	HU 2307/90 A	9/1991	Hungary	Coverpage	X
	BE 877 356	10/1979	Belgium		X
	EP 0390097	10/1990	Europe		
	WO 87/00834	12/1987	PCT		
	WO 90/10620	9/1990	PCT		
	WO 92/21355	12/1992	PCT		
	WO 93/07883	4/1993	PCT		
	WO 96/40153	12/1996	PCT		
	WO 99/49870	10/1999	PCT		

### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

SAC	AA	1UPHEALTH Diseases & Conditions, Secondary Hyperparathyroidism (7/2/03) <a href="http://www.1uphealth.com/health/secondary_hyperparathyroidism_treatment.htm">http://www.1uphealth.com/health/secondary_hyperparathyroidism_treatment.htm</a>
	AB	Abbott Laboratories, Kidney Disease (1/29/03) <a href="http://abbot.com/disease/kidney_disease.htm">http://abbot.com/disease/kidney_disease.htm</a>
	AC	Acchiardo, Sergio R., <i>et al.</i> , Efficacy of Pulse Dose Oral 1 <sub>α</sub> -Hydroxyvitamin D <sub>2</sub> (1 <sub>α</sub> -OH-D <sub>2</sub> ) as a Therapy for Secondary Hyperparathyroidism (HPT) in Hemodialysis (HD) Patients (PTS), Abstract Presented at the American Society of Nephrology, November 2-5, 1997, San Antonio, Texas
	AD	Aubia, J., <i>et al.</i> , <i>Proc Eur Dial Transplant Assoc Eur Ren Assoc</i> , 21:902-908 (1985) PMID 3991589 Abstract
	AE	Avioli, L., <i>Calcif. Tissue Int.</i> 65:292-294 (1999)
	AF	Barton, D. <i>et al.</i> , "Synthetic Uses of Steroidal Ring & Diene Protection: 22,23-Dihydroergosterol," <i>JCS Perkin I</i> , (1976) pp. 821-826.
	AG	BeActive: About Chronic Kidney Disease, 1/29/03, <a href="http://beactive.com/aboutckd">http://beactive.com/aboutckd</a>
	AH	Beer, <i>et al.</i> , "A Phase I Trial of Pulse Calcitriol in Patients with Refractory Malignancies," <i>Cancer</i> , (June 15, 2001) 91:12:2431-2439.
	AI	Beer, <i>et al.</i> , "Weekly High-Dose Calcitriol and Docetaxel in Advanced Prostate Cancer," <i>Seminars in Oncology</i> , Suppl 15 (August 2001) 28:4:49-55.
	AJ	Beer, T. <i>et al.</i> , "Weekly High-Dose Calcitriol and Docetaxel in Metastatic Androgen-Independent Prostate Cancer," <i>Journal of Clinical Oncology</i> , (Jan. 2003) 21:1:123-128.
	AK	Bischoff, H.A. <i>et al.</i> , <i>Arch. Phys. Med. Rehabil.</i> 80:54-58 (1999).
	AL	Bischoff, H.A. <i>et al.</i> , <i>Histochem J</i> 33:19-24 (2001)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE  
(Rev. 2-92) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.: 017620-9381

SERIAL NO.: 10/766,749

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT:

APPLICANT: Joyce C. Knutson

(Use several sheets if necessary)

FILING DATE: January 28, 2004

GROUP: 1614

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

SAQ	AM	Blazsek, I. <i>et al.</i> "Combined Differentiation Therapy in Myelodysplastic Syndrome with Retinoid Acid, 1 $\alpha$ ,25 Dihydroxyvitamin D <sub>3</sub> , and Prednisone," <i>Cancer Detect. Prev.</i> (1992) 16:4:259-264.
	AN	Braunwald, E. <i>et al.</i> , <i>Harrison's Principles of Internal Medicine: Part Eleven, "Disorders of Bone and Mineral Metabolism,"</i> Chapter 335, McGraw-Hill, New York, (1987) pp. 1860-1865.
	AO	Brautbar, N. "Osteoporosis: Is 1,25-(OH) <sub>2</sub> D <sub>3</sub> of Value in Treatment?" <i>Nephron</i> (1986) 44:161-166.
	AP	BROWN, C. <i>et al.</i> , Revisiting Hypocalciuria of Early Chronic Renal Insufficiency (CRI), Abstract Presented at the American Society of Nephrology, November 1999, Miami, Florida.
	AQ	Brown, J.P. <i>et al.</i> , "Serum Bone Gla-Protein: A Specific Marker for Bone Formation in Postmenopausal Osteoporosis," <i>Lancet</i> , (1984) 1:1091-1093.
	AR	Brown, S., <i>et al.</i> , <i>J. Clinical Endocrinology and Metabolism</i> 85(2): 868-872 (2000)
	AS	Caniggia, A. <i>et al.</i> , "Effect of a Long-Term Treatment with 1,25-Dihydroxyvitamin D <sub>3</sub> on Osteocalcin in Postmenopausal Osteoporosis," <i>Calcified Tissue Int.</i> , (1986) 38:328-332.
	AT	Chapuy, M.C. and Meunier, P.J., "Vitamin D insufficiency in adults and the elderly", <i>Vitamin D</i> , Feldman D, Glorieux FH, Pike JW (eds) Academic Press, San Diego, CA pp. 679-693 (1997)
	AU	Chesney, R.W., <i>et al.</i> , 1 $\alpha$ Hydroxyvitamin D <sub>2</sub> (1-OH-D <sub>2</sub> ): Initial Results from U.S. Phase 3 Trials in Hemodialysis Patients with Secondary Hyperparathyroidism, Abstract Presented at the XXXV Congress of the ERA-EDTA European Renal Association, September 21-24, 1997, Jerusalem, Israel.
	AV	Cho, Y.L. <i>et al.</i> , "Combined Effects of 1,25-Dihydroxyvitamin D <sub>3</sub> and Platinum Drugs on the Growth of MCF-7 Cells," <i>Cancer Research</i> , (June 1991) 51:2848-2853.
	AW	Christiansen, C. <i>et al.</i> , "Prevention of Early Postmenopausal Bone Loss: Controlled 2-Year Study in 315 Normal Females," <i>Europ J Clin Invest.</i> , (1980) 10:273-279.
	AX	Civitelli, R., <i>Calcif. Tissue Int.</i> 57:409-414 (1995)
	AY	Coburn, J.W. <i>et al.</i> , Use of Intravenous 1 $\alpha$ -Hydroxyvitamin D <sub>2</sub> in Hemodialysis Patients with Moderate-to-Severe Secondary Hyperparathyroidism, Abstract Presented at the 1998 Joint Meeting of the ASBMR and the International Bone & Mineral Society, December 1-6, 1998, San Francisco, California.
SAQ	AZ	Coburn, J.W., <i>et al.</i> , 1 $\alpha$ -Hydroxy-Vitamin D <sub>2</sub> (1-OH-D <sub>2</sub> ) Suppresses PTH Safely in Dialysis Patients with Secondary Hyperparathyroidism, Abstract Presented at the International Symposium on Advances in Renal Osteodystrophy, March 1997, Oviedo, Spain.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE  
(Rev. 2-92) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.: 017620-9381

SERIAL NO.: 10766,749

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT:

APPLICANT: Joyce C. Knutson

(Use several sheets if necessary)

FILING DATE: January 28, 2004

GROUP: 1614

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

SA	BA	Coburn, J.W., <i>et al.</i> , Effect of Severity of Secondary Hyperparathyroidism on the Response to $1\alpha$ Hydroxyvitamin D <sub>2</sub> ( $1\_D_2$ ) IN Hemodialysis Patients, Abstract Presented at the International Congress of Nephrology, May 2-6, 1999, Buenos Aires, Argentina.
	BB	Coburn, J.W., <i>et al.</i> , Hyperphosphatemia Impairs the Suppression of Intact PTH by Treatment with $1\alpha$ Hydroxyvitamin D <sub>2</sub> in Secondary Hyperparathyroidism: A Prospective, Controlled Study, Abstract Presented at the Official Satellite Symposium, May 7-9, 1999, Iguazu Falls, Brazil.
	BC	Coburn, W.J., <i>et al.</i> , Factors predicting Hypercalcemia during Treatment with $1\alpha$ Hydroxyvitamin D <sub>2</sub> : Role of Pre-treatment Serum Calcium and Bone Turnover, Abstract Presented at the American Society of Nephrology, November 1999, Miami, Florida.
	BD	Coresh, J., <i>et al.</i> , Prevalence of Chronic Kidney Disease and Decreased Kidney Function in the Adult US Population: Third National Health and Nutrition Examination Survey, <i>American Journal of Kidney Diseases</i> , (Jan. 2003) 41:1:1-12.
	BE	Crump, D.R. <i>et al.</i> , "(22S)-Hydroxyvitamin D <sub>4</sub> ," <i>J.C.S. Perkins Trans. I</i> , (1973) pp. 2731-2733.
	BF	Davies, E.B., <i>et al.</i> , Synthesis of $1,24(S)$ -Dihydroxyvitamin D <sub>2</sub> in Disorders of Mineral Metabolism in Humans, Abstract Presented at the ASBMR, September 1995, Baltimore, Maryland.
	BG	DeChant, K.L. and Goa, K.L., <i>Drugs &amp; Aging</i> , 5(4):300-317 (1994)
	BH	Defacque, H. <i>et al.</i> , "Different Combinations of Retinoids and Vitamin D <sub>3</sub> Analogs Efficiently Promote Growth Inhibition and Differentiation of Myelomonocytic Leukemia Cell Lines," <i>J. Pharmacology and Experimental Therapeutics</i> , (1994) 271:193-199.
	BI	DeLuca <i>et al.</i> , "Synthesis, Biological Activity, and Metabolism of $22,23\text{-}^3\text{H}$ -Vitamin D <sub>4</sub> ," <i>Arch. Biochem. Biophys.</i> , (1968) 124:122-128.
	BJ	Douthat, W.G., <i>et al.</i> , Treatment of refractory secondary hyperparathyroidism with ethanol injection: The importance of glandular volume, <i>Kidney Intl.</i> 63:85:S101-S104
	BK	Drueke, T.B., Control of Secondary Hyperparathyroidism by Vitamin D Derivatives, <i>American Journal of Kidney Diseases</i> . 37:1 [Suppl 2] (Jan 2001) S58-S61.
SA	BL	Drueke, T.B., Treatment of secondary hyperparathyroidism with vitamin D derivatives and calcimimetics before and after start of dialysis, <i>Nephrol Dial. Transplant</i> , [Suppl 11] (2002) 17:20-22.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE  
(Rev. 2-92) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.: 017620-9381

SERIAL NO.: 10/766,749

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT:



APPLICANT: Joyce C. Knutson.

(Use several sheets if necessary)

FILING DATE: January 28, 2004

GROUP: 1614

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

	BM	Duda <i>et al.</i> , "1,25-Dihydroxyvitamin D Stimulation Test for Osteoblast Function in Normal and Osteoporotic Postmenopausal Women," <i>J. Clinic Inves.</i> , (1987) 79:1249-1253.
	BN	Eastell, R and Roggs, B.L., "Vitamin D and osteoporosis", <u>Vitamin D</u> , Feldman D, Glorieux FH, Pike JW (eds) Academic Press, San Diego, CA pp. 695-711 (1997)
	BO	Endo, K. <i>et al.</i> , "Effect of Combination Treatment with Vitamin D Analog (OCT) and a Bisphosphonate (AHPrBP) in a Nude Mouse Model of Cancer-Associated Hypercalcemia," <i>Journal of Bone and Mineral Research</i> , (1998) 13:9:1378-1383.
	BP	Engstrom, G.W. <i>et al.</i> , <i>Archives of Biochemistry and Biophysics</i> 270(2) 432-440 (May 1, 1989)
	BQ	Foldes, J. <i>et al.</i> , "Long Term Treatment with 1 $\alpha$ (OH)D <sub>3</sub> for Postmenopausal Osteoporosis: Efficacy and Safety," <i>Osteoporosis</i> , (1987) 2:971-973.
	BR	Francis, R.M. <i>et al.</i> , <i>Osteoporosis Int.</i> 6:284-290 (1996)
	BS	Francis, R.M., <i>Calcif. Tissue Int.</i> 60:111-114 (1997)
	BT	Frazao, <i>et al.</i> , Use of 1 $\alpha$ Hydroxyvitamin D <sub>2</sub> (1-D <sub>2</sub> ) in 121 Hemodialysis Patients with Secondary Hyperparathyroidism: A Phase 3 Trial, Abstract Presented at the American Society of Nephrology, November 2-5, 1997, San Antonio, Texas.
	BU	Frazao, J.M. <i>et al.</i> , Comparison of Intravenous with Oral 1 $\alpha$ Hydroxyvitamin D <sub>2</sub> (1-D <sub>2</sub> ) in Hemodialysis Patients with Secondary Hyperparathyroidism, Abstract Presented at the American Society of Nephrology, October 25-27, 1998, Philadelphia, Pennsylvania.
	BV	Frazão, J.M., <i>et al.</i> , 1 $\alpha$ -Hydroxy-Vitamin D <sub>2</sub> (1-OH-D <sub>2</sub> ): An Effective and Safe Oral Agent for Suppressing PTH in Dialysis Patients with Secondary Hyperparathyroidism, Abstract Presented at the International Congress of Nephrology, May 25-29, 1997, Sydney, Australia.
	BW	Frazão, J.M., <i>et al.</i> , Efficacy and Safety of Intermittent Oral 1 $\alpha$ (OH)-Vitamin D <sub>2</sub> in Suppressing Secondary Hyperparathyroidism in Hemodialysis Patients, <i>Dialysis &amp; Transplantation</i> (September) 1997, 8 pgs.
	BX	Frazão, J.M., <i>et al.</i> , Intermittent Doxercalciferol (1 $\alpha$ -Hydroxyvitamin D <sub>2</sub> ) Therapy for Secondary Hyperparathyroidism, <i>American Journal of kidney Diseases</i> , Vol. 36, No. 3 (September) 2000, 550-561.
	BY	Frazão, J.M., <i>et al.</i> , Intermittent oral 1 $\alpha$ -hydroxyvitamin D <sub>2</sub> effective and safe for the suppression of secondary hyperparathyroidism in haemodialysis patients, <i>Nephrology Dialysis Transplantation</i> , 1998, 13: [Suppl 3]: 68-72.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE  
(Rev. 2-92) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.: 017620-9381

SERIAL NO.: 10/766,749

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT:



APPLICANT: Joyce C. Knutson.

(Use several sheets if necessary)

FILING DATE: January 28, 2004

GROUP: 1614

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

	BZ	Frazao, J.M., <i>et al.</i> , Serum Osteocalcin and Bone Alkaline Phosphatase in Hemodialysis Patients with Secondary Hyperparathyroidism Treated with 1 $\alpha$ Hydroxyvitamin D <sub>2</sub> : Evidence for Direct Action, Abstract Presented at the 1998 Joint Meeting of the ASBMR and the International Bone and Mineral Society, December 1-6, 1998, San Francisco, California.
	CA	Friedman, T.C. and Norris, K.C., The role of vitamin D in mild to moderate chronic kidney disease, <i>Trends in Endocrinology &amp; Metabolism</i> , Vol. 13, No. 5, July 2002, 189-194.
	CB	Fukagawa, M., Pathogenesis and Treatment of Secondary Hyperparathyroidism in Chronic Renal Failure, 7/2/03 <a href="http://www.uninet.edu/cin2000/conferences/fukagawa/fukagawa.html">http://www.uninet.edu/cin2000/conferences/fukagawa/fukagawa.html</a>
	CC	Gillespie, W.J., <i>et al.</i> , Abstract, <i>The Cochrane Library</i> , issue 2, 2001
	CD	Glerup, H. "Investigations on the role of vitamin D in muscle function," Ph.D. Thesis, Aarhus Bone and Mineral Research Group, University of Asrhus, Denmark (1999)
	CE	Goodman, W., <i>et al.</i> <i>Renal Osteodystrophy in Adults and Children</i> , Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 3 <sup>rd</sup> edition, Favus ed. (1996).
	CF	Grab, W. Z. "Die Auswertung der Antirachitischen Wirksamkeit Neuer Sterinderivate im Versuch an Ratten und Kuken," <i>Physiol. Chem.</i> , (1936) 243:63-89.
	CG	Grady, D. <i>et al.</i> , <i>J. Clin. Endocrinol. &amp; Metab.</i> 73:1111-1117 (1991)
	CH	Guidelines for the Clinical Evaluation of Drugs Used in the Treatment of Osteoporosis, HEW (FDA) 80-3094, (1979) pp. 5-6.
	CI	Haas, H.G., <i>Horm. Metab. Res.</i> 11:168-171 (1979)
	CJ	Heikinheimo, R <i>et al.</i> , (1992) <i>Calcif Tissue Int</i> 51:105-110
	CK	Hershberger, P. <i>et al.</i> "Calcitriol (1,25-Dihydroxycholecalciferol) Enhances Paclitaxel Antitumor Activity in Vitro and in Vivo and Accelerates Paclitaxel-induced Apoptosis," <i>Clinical Cancer Research</i> , (April 2001) 7:1043-1051.
	CL	Hoikka, V. <i>et al.</i> , "Treatment of Osteoporosis with 1-Alpha-Hydroxycholecalciferol and Calcium," <i>Acta. Med. Scand.</i> (1980) 207:221-224.
	CM	Holick, "Noncalcemic Actions of 1,25-Dihydroxyvitamin D <sub>3</sub> and Clinical Applications", <i>Bone</i> , Vol. 17, No. 2, August 1995, pp. 107S-111S, PMID 5879891, Abstract only.
	CN	Holick, M.F., "Noncalcemic Actions of 1,25-Dihydroxyvitamin D <sub>3</sub> and Clinical Applications", <i>Bone</i> , (1995) 17:2:107S-110S.
	CO	Horst <i>et al.</i> , "Discrimination in the Metabolism of Orally Dosed Ergocalciferol and Cholecalciferol by the Pig, Rat and Chick," <i>Biochem. J.</i> , (1982) 204:185-189.
	CP	Horst <i>et al.</i> , "Quantitation of Vitamin D and its Metabolites and Their Plasma Concentrations in Five Species of Animals," <i>Anal. Biochem.</i> , (1981) 116:189-203.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE  
(Rev. 2-92) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.: 017620-9381

SERIAL NO.: 10/766,749

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT:



APPLICANT: Joyce C. Knutson.

(Use several sheets if necessary)

FILING DATE: January 28, 2004

GROUP: 1614

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

	CQ	Horst, R.L. <i>et al.</i> , <i>Biochem.</i> 29:578-582 (1990)
	CR	Horst, R.L., <i>et al.</i> , Effects of 24-Hydroxyvitamin D <sub>2</sub> and 25-Hydroxyvitamin D <sub>2</sub> Dosing on Plasma Concentrations of Calcium, Phosphorus and Vitamin D Metabolites in Vitamin D <sub>3</sub> Replete Rats, Abstract Presented at the 1998 Joint Meeting of the ASBMR and the International Bone and Mineral Society, December 1-6, 1998, San Francisco, California.
	CS	Ikeda, K and Ogata, E., <i>Mechanisms of Aging &amp; Development</i> 116:103-111 (2000)
	CT	Johnson, C. <i>et al.</i> , "Vitamin D-related Therapies in Prostate Cancer," <i>Cancer and Metastasis Review</i> 21, (2002) pp. 147-158.
	CU	Johnson, C., <i>et al.</i> , Analysis of a Large Provider Database to Compare Clinical Experiences with Calcitriol and Paricalcitol, Abstract Presented at the American Society of Nephrology, October 2001, San Francisco, California.
	CV	Jones, G., <i>et al.</i> , Cultured human keratinocytes both active and catabolise 1 $\alpha$ hydroxyvitamin D <sub>2</sub> analogs, Abstract Presented at the American Society of Bone and Mineral Research, September 30- October 4, 1999, St. Louis, Missouri.
	CW	Kanis, J.A. <i>et al.</i> , "Guidelines for Clinical Trials in Osteoporosis, A Position Paper of the European Foundation for Osteoporosis," <i>Osteoporosis Int.</i> , (1991) 1:182-188.
	CX	Kantorovich, V., <i>et al.</i> , <i>J. Clinical Endocrinology and Metabolism</i> 85(10): 3541-3543 (2000)
	CY	Khaw, K.T. <i>et al.</i> , <i>Br. Med. J.</i> 305:273-277 (1992)
	CZ	Kim, S. <i>et al.</i> , "Potentiation of 1,25-Dihydroxyvitamin D <sub>3</sub> -Induced Differentiation of Human Promyelocytic Leukemia Cells into Monocytes by Costunolide, a Germacranolide Sesquiterpene Lactone," <i>Biochem. Pharmacology</i> , (2002) 64:1233-1242.
	DA	Klempa, I., <i>Chirurg</i> , Oct; 70(10):1089-101, (1999) PMID 10550338 Abstract only
	DB	Knutson, J. <i>et al.</i> , <i>Biochemical Pharmacology</i> 53:829-837 (1997)
	DC	Kocienski, P.J. <i>et al.</i> , "Calciferol and its Relatives. A Synthesis of Vitamin D <sub>4</sub> ," <i>J.C.S. Perkins I</i> , (1979) pp. 1290-1293.
	DD	Lau, K.-H. W. and Baylink, D. J., <i>Calcif. Tissue Int.</i> 65:295-306 (1999)
	DE	Leary, E.T., <i>et al.</i> , Serum Bone Turnover Markers in Chronic Renal Insufficiency Patients Treated with Doxercalciferol (1 $\alpha$ -Hydroxyvitamin D <sub>2</sub> ), Abstract Presented at the American Society of Bone and Mineral Research, October 2001, Phoenix, Arizona.
	DF	Londowski, J.M. <i>et al.</i> , "Biological Activity of the C-1, C-3, C-25, $\beta$ -D-Glucopyranosides of 1,25-Dihydroxyvitamin D <sub>3</sub> ," <i>J. Pharmacology Expt. Ther.</i> , (1986) 237:3:837-840.
	DG	Majewski, <i>et al.</i> , "Inhibition of Tumor Cell-Induced Angiogenesis by Retinoids, 1,25-Dihydroxyvitamin D <sub>3</sub> and their Combination," <i>Cancer Letters</i> , (1993) 75:35-39.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE  
(Rev. 2-92) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.: 017620-9381  
SERIAL NO.: 10766,749  
APPLICANT: Joyce C. Knutson  
FILING DATE: January 28, 2004  
GROUP: 1614

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT:

(Use several sheets if necessary)

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

500	DH	Malluche, <i>et al.</i> , "Update on vitamin D and its newer analogues: Actions and rationale for treatment in chronic renal failure," <i>Kidney International</i> , (2002) 62: 367-374.
	DI	Manchand <i>et al.</i> , <i>J. Org. Chem.</i> 60:6574 (1995)
	DJ	Martin and DeLuca, "Calcium Transport," <i>Am. J. Physiol.</i> , 216(6):1351-1359 (1969).
	DK	Martin, K.J and Gonzales, E.A., Vitamin D Analogues for the Management of Secondary Hyperparathyroidism, <i>American Journal of Kidney Diseases</i> , 38:5 [Suppl 5] (Nov 2001) S34-S40
	DL	Martin, K.J. <i>et al.</i> , <i>J. Am. Soc. Nephrol.</i> 9:1427-1432 (1998)
	DM	Massheimer, V., <i>et al.</i> , <i>Calcif Tissue Int</i> , 64:173-178 (1999)
	DN	Mathias, C.J. <i>et al.</i> , "Tumor-Selective Radiopharmaceutical Targeting Via Receptor-Mediated Endocytosis of Gallium-67-Deferoxamine-Folate," <i>J. Nucl. Med.</i> (1996), 37(6):1003-1008.
	DO	Maung, H.M., <i>et al.</i> , Doxercalciferol [Hectorol®] Lowers PTH Levels without Causing Hypercalcemia in Patients with Chronic Renal Insufficiency and Secondary Hyperparathyroidism, Abstract Presented at the American Society of Nephrology, October 2001, San Francisco, California.
	DP	Maung, H.M., <i>et al.</i> , Doxercalciferol Therapy Safely Suppresses PTH Levels in Chronic Renal Insufficiency with Secondary Hyperparathyroidism, Abstract Presented at the American Society of Nephrology, October 2000, Toronto, Canada.
	DQ	Mawer, E.B., <i>et al.</i> , 1,24(S)-Dihydroxyvitamin D <sub>2</sub> , a biologically active analogue of vitamin D, is a naturally occurring metabolite in humans, Abstract Presented at the Bone & Tooth Society, March 27, 1995, Warwick, United Kingdom.
	DR	Mazess, R.B., <i>et al.</i> , Intravenous Paricalcitol had Increased Side Effects in Hemodialysis Patients Compared to Calcitriol, Abstract Presented at the NKF Clinical Meeting, April 18-20, 2002, Chicago, Illinois.
	DS	McDonald, F.G., "The Multiple Nature of Vitamin D," <i>J. Biol. Chem.</i> 114, (1936) 1xv.
	DT	MD Consult, <a href="http://home.mdconsult.com/das/news/body/1/ctt/0/74157/1.html">http://home.mdconsult.com/das/news/body/1/ctt/0/74157/1.html</a> (2001)
	DU	MEDLINEplus Medical Encyclopedia: Secondary hyperparathyroidism, (1/29/03) <a href="http://www.nlm.nih.gov/medlineplus/ency/article/000318.htm">http://www.nlm.nih.gov/medlineplus/ency/article/000318.htm</a>
	DV	MedTech1.com, Research Center: Medical Conditions, Kidney Disease (1/29/03) <a href="http://www.medtech1.com/research_center/cond20.cfm?cond_id=66">http://www.medtech1.com/research_center/cond20.cfm?cond_id=66</a>
	DW	<i>Merck Index</i> , S. Budavari (ed.), 11th ed., Merck & Co., Rahway, N.J. (1989) pp. 1579, #9930
500	DX	Miller <i>et al.</i> , <i>Cancer Res.</i> 52:515-520 (1992)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE  
(Rev. 2-92) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.: 017620-9381

SERIAL NO.: 10766,749

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT:



APPLICANT: Joyce C. Knutson.

(Use several sheets if necessary)

FILING DATE: January 28, 2004

GROUP: 1614

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

	DY	Moffatt, K. <i>et al.</i> , "1 $\alpha$ ,25-Dihydroxyvitamin D <sub>3</sub> and Platinum Drugs Act Synergistically to Inhibit the Growth of Prostate Cancer Cell Lines," <i>Clinical Cancer Research</i> , (March 1999) 5:695-703.
	DZ	Morris, H.A. <i>et al.</i> , <i>Calcif. Tissue Int.</i> 49:240-243 (1991)
	EA	Muindi, J. <i>et al.</i> , "Pharmacokinetics of High-Dose Oral Calcitriol: Results From a Phase 1 Trial of Calcitriol and Paclitaxel," <i>Clinical Pharmacology &amp; Therapeutics</i> , (Dec. 2002) pp. 648-659.
	EB	Need, A., <i>et al.</i> , <i>Calcif Tissue Int.</i> 61:6-9 (1997)
	EC	Nemeto, H. <i>et al.</i> , "A Stereoselective Synthesis of 1 $\alpha$ - Hydroxy-Vitamin D <sub>3</sub> ," <i>CHEMISTRY LETTERS</i> , (1985) 8:1131-1132.
	ED	Nieto, J., <i>et al.</i> , <i>Pediatr Nephrol</i> , Feb; 11(1):65-68, (1997) PMID 9035174 Abstract only
	EE	NIH Publication No. 95-3425 <a href="http://www.niddk.nih.gov/health/endo/pubs/hyper/hyper.htm">http://www.niddk.nih.gov/health/endo/pubs/hyper/hyper.htm</a> (Feb 1995)
	EF	Nishigaichi <i>et al.</i> , <i>Chem. Lett.</i> 961 (1996)
	EG	NKF K/DOQI Guidelines, Part 4, Guideline 1. Definition and stages of Chronic Kidney Disease (1/29/03) <a href="http://www.kidney.org/professionals/doqi/kdoqi/p4_class_g1.htm">http://www.kidney.org/professionals/doqi/kdoqi/p4_class_g1.htm</a>
	EH	NKF K/DOQI Guidelines, Part 6, Guideline 10. Association of Level of GFR with Bone Disease and Disorders of Calcium and Phosphorus Metabolism (1/29/03) <a href="http://www.kidney.org/professionals/doqi/kdoqi/p6_comp_g10.htm">http://www.kidney.org/professionals/doqi/kdoqi/p6_comp_g10.htm</a>
	EI	NKF K/DOQI Guidelines, Part 7, Guideline 13. Factors Associated with Loss of Kidney Function in Chronic Kidney Disease (1/29/03) <a href="http://www.kidney.org/professionals/doqi/kdoqi/p7_risk_g13.htm">http://www.kidney.org/professionals/doqi/kdoqi/p7_risk_g13.htm</a>
	EJ	Nordin, B.E.C. <i>et al.</i> , <i>Calcif. Tissue Int.</i> 65:307-310 (1999)
	EK	Obrador, G.T., <i>et al.</i> , Chronic Kidney Disease in the United States: An Underrecognized Problem, <i>Seminars in Nephrology</i> , Vol. 22, No. 6 (November) 2002, 441-448.
	EL	Ooms, ME <i>et al.</i> , <i>J. Bone Miner Res.</i> 10:1177-1184 (1995)
	EM	Orimo, H. <i>et al.</i> , <i>Calcif. Tissue Int.</i> 54:370-376 (1994)
	EN	Paaren <i>et al.</i> , "Direct C(1) Hydroxylation of Vitamin D <sub>3</sub> and Related Compounds," <i>J. Org. Chem.</i> , (1980) 45:3253.
	EO	Packman, K. <i>et al.</i> "Combination Treatment of MCF-7 Xenografts with the Vitamin D <sub>3</sub> Analog EB1089 and Antiestrogens," (Vitamin D Endocrine Workshop, Nashville, TN May 27-June 1, 2000) pp. 511-514.
	EP	Guyton, A.C. and Hall, J.E., "Parathyroid Hormone, Calcitonin, Calcium/Phosphate, Vitamin D, Bone, Teeth", <i>Textbook of Medical Physiology</i> , 10 <sup>th</sup> ed., Philadelphia: Saunders, Unit XIV, Ch. 79, Endocrinology and Reproduction, pp. 985-1002 (August 2000).
	EQ	Parfitt, A.M., <i>Drugs</i> 36:513-520 (1988)

EXAMINER

DATE CONSIDERED

3/2/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE  
(Rev. 2-92) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.: 017620-9381

SERIAL NO.: 10/766,749

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT:

APPLICANT: Joyce C. Knutson.

(Use several sheets if necessary)

FILING DATE: January 28, 2004

GROUP: 1614

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

SAO	ER	Part One. Executive Summary, <i>American Journal of Kidney Diseases</i> , Vol. 39, No. 2, Suppl 1 (February), 2002, S17-S31.
	ES	Pattanaungkul, S., <i>et al.</i> , Relationship of Intestinal Calcium Absorption to 1,25-Dihydroxyvitamin D [ $1,25(\text{OH})\text{D}_2$ ] Levels in Young <i>Versus</i> Elderly Women: Evidence for Age-Related Intestinal Resistance to 1,25(OH) $\text{D}_2$ Action, <i>J. Clinical Endocrinol. &amp; Metab.</i> (2000) 85:11 4023-4027.
	ET	<i>Physician's Desk Reference</i> , Edition 43:1746-1748.
	EU	Podenphant, J. <i>et al.</i> , "Serum Bone Gla Protein and Other Biochemical Estimates of Bone Turnover in Early Postmenopausal Women During Prophylactic Treatment for Osteoporosis," <i>Acta Med Scand</i> , (1985) 218:329-333.
	EV	Pouilles, J.M. <i>et al.</i> , "Prevention of Early Postmenopausal Bone Loss with 1 $\alpha$ -Hydroxy Vitamin D $_3$ , A Three-Year Prospective Study," <i>Clin Rheumatol.</i> 11, 4 (1992) pp. 492-497.
	EW	Ravid, A. <i>et al.</i> , "1,25-Dihydroxyvitamin D $_3$ Enhances the Susceptibility of Breast Cancer Cells to Doxorubicin-induced Oxidative Damage," <i>Cancer Research</i> , (February 15, 1999) 59:862-867.
	EX	Reeve, L.E. <i>et al.</i> , "Biological Activity of 1 $\alpha$ -hydroxy Vitamin D $_2$ in the Rat," <i>Arch. Biochem. Biophys.</i> (Feb. 1978) 186:1:164-167.
	EY	Reilly, R.F., <i>et al.</i> , Chronic Kidney Disease: A New Approach to an Old Problem, <i>Connecticut Medicine</i> Vol. 66, No. 10, (October) 2002, 579-283.
	EZ	Sairanen, S. <i>et al.</i> , <i>Calcif. Tissue Int.</i> 67:122-127 (2000)
	FA	Sato, F. <i>et al.</i> , "Biological Activity of 1 $\alpha$ ,25-Dihydroxyvitamin D Derivatives - 24- <i>epi</i> -1 $\alpha$ ,25-Dihydroxyvitamin D-2 and 1 $\alpha$ ,25-Dihydroxyvitamin D-7," <i>Biochim. Biophys. Acta</i> , (1991) 1091:188-192.
	FB	ScienceBlog, 19.2 Million U.S. Adults have Chronic Kidney Disease (1/29/03) <a href="http://www.scienceblog.com/community/article649.html">http://www.scienceblog.com/community/article649.html</a>
	FC	Shiraishi, A. <i>et al.</i> , <i>Calcif. Tissue Int.</i> 65:311-316 (1999)
	FD	Shiraki, M., <i>Osteoporosis Int. Suppl.</i> 1:S176-180 (1993)
	FE	Silverberg, S., <i>Endocrinology and Metabolism Clinics</i> 29(3):Sept (2000)
	FF	Silverberg, S.J. <i>et al.</i> , <i>New England J. Med.</i> 320(5):277-281 (1989)
	FG	Siwinska, A. <i>et al.</i> "Potentiation of the Antiproliferative Effect <i>In Vitro</i> of Doxorubicin, Cisplatin and Genistein by New Analogues of Vitamin D," <i>Anticancer Research</i> , (2001) 21:1925-1929.
	FH	Sjoden <i>et al.</i> , "Effects of 1 OH $\text{D}_2$ on Bone Tissue," <i>Acta. Endocrinol.</i> (Copenh.) (Aug. 1984) 16:4:564-568.
	FI	Skowronski <i>et al.</i> , "Vitamin D and Prostate Cancer: 1,25 Dihydroxyvitamin D $_3$ Receptors and Actions in Human Prostate Cancer Cell Lines" <i>Endocrinology</i> , (1993) 132: 1952-1960.
SAO	FJ	Skowronski <i>et al.</i> , <i>Endocrinology</i> 136:20-26 (1995)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE  
(Rev. 2-92) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.: 017620-9381

SERIAL NO.: 10/766,749

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT:

APPLICANT: Joyce C. Knutson

(Use several sheets if necessary)

FILING DATE: January 28, 2004

GROUP: 1614

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

590	FK	Slapak, C. <i>et al.</i> , "Treatment of Acute Myeloid Leukemia in the Elderly with Low-Dose Cytarabine, Hydroxyurea, and Calcitriol," <i>Amer. J. Hematology</i> , (1992) 41:178-183.
	FL	Sommerfeldt <i>et al.</i> , "Metabolism of Orally Administered [ <sup>3</sup> H]Ergocalciferol and [ <sup>3</sup> H]Cholecalciferol by Dairy Calves," <i>J. Nutr.</i> , (1983) 11:2595-2600.
	FM	Song, X.D. <i>et al.</i> , "Bryostatin-1 and 1 $\alpha$ ,25-Dihydroxyvitamin D <sub>3</sub> Synergistically Stimulate the Differentiation of NB4 Acute Promyelocytic Leukemia Cells," <i>Leukemia</i> , (1999) 13:275-281.
	FN	Strugnell <i>et al.</i> , "Metabolism of a Cyclopropane-Ring-Containing Analog of 1 $\alpha$ -Hydroxyvitamin D <sub>3</sub> in a Hepatocyte Cell Model," <i>Biochem. Pharm.</i> , (1990) 40:333-341.
	FO	Strugnell, S.A., <i>et al.</i> , Doxercalciferol is Several-Fold Less Toxic than Calcitriol in Rats, Abstract Presented at the American Society of Nephrology, October 2001, San Francisco, California.
	FP	Studzinski, G. <i>et al.</i> , "Potentiation by 1- $\alpha$ ,25-Dihydroxyvitamin D <sub>3</sub> of Cytotoxicity to HL-60 Cells Produced by Cytarabine and Hydroxyurea," <i>J. National Cancer Inst.</i> , (April 1986) 76:4:641-648.
	FQ	Suzuki, Y. <i>et al.</i> , "The Enhancement of the Chemotherapeutic Effects on Human Prostate Cancer Cell - The Combination with the Growth Factor Interaction Inhibitor (Suramin)," <i>Acta Urologica</i> (1993) 12:1215-1220, (Abstract).
	FR	Swami, S. <i>et al.</i> , "1 $\alpha$ ,25-Dihydroxyvitamin D <sub>3</sub> Down-Regulates Estrogen Receptor Abundance and Suppresses Estrogen Actions in MCF-7 Human Breast Cancer Cells," <i>Clinical Cancer Research</i> , (Aug. 2000) 6:3371-3379.
	FS	Tachibana, Y. (Nisshin Flour Milling Co.), "Preparation of 1 Beta-Hydroxyvitamin D <sub>2</sub> and D <sub>3</sub> ," <i>CHEMICAL ABSTRACTS</i> , (1990) 113:1:6688 Col. 2 Abstract No. 6683y.
	FT	Tan, A.U., <i>et al.</i> , Effective suppression of parathyroid hormone by 1 $\alpha$ -hydroxyvitamin D <sub>2</sub> in hemodialysis patients with moderate to severe secondary hyperparathyroidism, <i>Kidney International</i> , Vol. 51 (1997) 317-323.
	FU	Tan, A.U., <i>et al.</i> , Efficacy of Intermittent 1 (OH)-Vitamin D <sub>2</sub> in Suppressing Secondary Hyperparathyroidism, Abstract Presented at the American Society of Nephrology, November 3-6, 1996, New Orleans, Louisiana.
	FV	Tan, A.U., <i>et al.</i> , Suppression of PTH by 1 (OH)-Vitamin D <sub>2</sub> in Hemodialysis Patients: Initial Results, Abstract Presented at the National Kidney Foundation, April 1996, Anaheim, California.
590	FW	Tan, A.U., <i>et al.</i> , Suppression of Secondary Hyperparathyroidism by 1 (OH)-Vitamin D <sub>2</sub> in Hemodialysis Patients, Abstract Presented at the International Congress of Nephrology, July 2-6, 1995, Madrid Spain.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered; whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE  
(Rev. 2-92) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.: 017620-9381

SERIAL NO.: 10/766,749

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT:



APPLICANT: Joyce C. Knutson.

(Use several sheets if necessary)

FILING DATE: January 28, 2004

GROUP: 1614

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

	FX	Tanaka, Y. <i>et al.</i> , "Biological Activity of 1,25-Dihydroxyvitamin D <sub>3</sub> in the Rat," <i>Endocrinology</i> (1973) 92:417-422.
	FY	Tanizawa, T., <i>Osteoporos. Int.</i> 9:163-170 (1999)
	FZ	Theiler, R. <i>et al.</i> , <i>Arch. Phys. Med. Rehabil.</i> 80:485-489 (1999)
	GA	Theiler, R. <i>et al.</i> , <i>Int. J. Vit. Nur. Res.</i> 68:36-41 (1998)
	GB	Thompson, S.P. <i>et al.</i> , <i>Brit. Edit. Soc. Bone Joint Surgery</i> , 72:1053-1056 (1990)
	GC	Tilyard, M.W. <i>et al.</i> , <i>New England J. Med.</i> 326:357-362 (1992)
	GD	Torres, R. <i>et al.</i> , "Etoposide Stimulates 1,25-Dihydroxyvitamin D <sub>3</sub> Differentiation Activity, Hormone Binding and Hormone Receptor Expression in HL-60 Human Promyelocytic Cells, <i>Molecular and Cellular Biochemistry</i> , (2000) 208:157-162.
	GE	Toss, G <i>et al.</i> , <i>Acta Med Scand</i> 208:87-89 (1980)
	GF	Tsuji, M. <i>et al.</i> , "Synthesis of 22,23-Dihydro-1 $\alpha$ ,25-Dihydroxyvitamin D <sub>2</sub> and its 24R-Epimer, New Vitamin D <sub>2</sub> Derivatives," <i>Bull. Chem. Soc. Jpn.</i> , (1990) 63:8:2233-2238.
	GG	Wang, Q. <i>et al.</i> , "1,25-Dihydroxyvitamin D <sub>3</sub> and All-trans-Retinoic Acid Sensitize Breast Cancer Cells to Chemotherapy-induced Cell Death," <i>Cancer Research</i> , (April 2000) 60:2040-2048.
	GH	Wang, X. <i>et al.</i> , "Inhibition of p38 MAP Kinase Activity Up-Regulates Multiple MAP Kinase Pathways and Potentiates 1,25-Dihydroxyvitamin D <sub>3</sub> -Induced Differentiation of Human Leukemia HL60 Cells," <i>Experimental Cell Research</i> , (2000) 258:425-437.
	GI	White <i>et al.</i> , <i>J. Chem. Soc. Perkin Trans.</i> 759 (1993)
	GJ	Wientroub, S. <i>et al.</i> , "The Dichotomy in the Effects of 1,25 Dihydroxy Vitamin D <sub>3</sub> and 24, 25 Dihydroxy Vitamin D <sub>3</sub> on Bone Gamma-Carboxyglutamic Acid-Containing Protein in Serum and Bone in Vitamin D-Deficient Rats," <i>Calcif. Tissue Int.</i> , (1987) 40:166-172.
	GK	Windaus, A. <i>et al.</i> , "Uber das Krystallisierte Vitamin D <sub>4</sub> ," <i>Z. Physiol. Chem.</i> , (1937) 247:185-188.
	GL	Yu, W. <i>et al.</i> , "Enhancement of 1,25- Dihydroxyvitamin D <sub>3</sub> - Mediated Antitumor Activity with Dexamethasone," <i>J. National Cancer Inst.</i> , (January 1998) 90:2:134-141.
	GM	Zerwekh <i>et al.</i> , "Short-Term 1,25-Dihydroxyvitamin D <sub>3</sub> Administration Raises Serum Osteocalcin in Patients with Postmenopausal Osteoporosis," <i>J. Clin. Endocrinol. Metabol.</i> (1985) 60:615-617.
	GN	Zerwekh, J.E. <i>et al.</i> , <i>J. Clin. Endocrinol. Metab.</i> 56:410-413 (1983) Abstract.
	GO	Guyton, A.C. and Hall, J.E., "Parathyroid Hormone, Calcitonin, Calcium/Phosphate, Vitamin D, Bone, Teeth", <i>Textbook of Medical Physiology</i> , 10 <sup>th</sup> ed., Philadelphia: Saunders, Unit XIV, Ch. 79, Endocrinology and Reproduction, pp. 985-1002 (August 2000).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE  
(Rev. 2-92) PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT:

(Use several sheets if necessary)

ATTY. DOCKET NO.: 017620-9381


SERIAL NO.: 10/766,749

APPLICANT: Joyce C. Knutson

FILING DATE: January 28, 2004

GROUP: 1614

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

	GP	Martin and DeLuca, "Influence of sodium on calcium transport by the rat small intestine" <i>Am. J. Physiol.</i> , 216(6):1351-1359 (1969).
---	----	--

EXAMINER

DATE CONSIDERED

  
3/2/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.